Document is current
Any future updates will be listed below
-
Authors
Aydin, Orhun Utku
Taha, Abdel Aziz
Hilbert, Adam
Khalil, Ahmed A.
Galinovic, Ivana
Fiebach, Jochen B.
Frey, Dietmar
Madai, Vince Istvan
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 23 March 2021
Accepted: 7 July 2021
First Online: 16 July 2021
Declarations
:
: The 1000Plus study was carried out with approval from the local Ethics Committee of Charité University Hospital Berlin (EA4/026/08). The study protocol was carried out in accordance with the Declaration of Helsinki.
: The study was carried out with written informed consent from all subjects in accordance with the Declaration of Helsinki.
: Dr. Madai reported receiving personal fees from ai4medicine outside the submitted work. Adam Hilbert reported receiving personal fees from ai4medicine outside the submitted work. Dr. Frey reported receiving grants from the European Commission, reported receiving personal fees from and holding an equity interest in ai4medicine outside the submitted work. There is no connection, commercial exploitation, transfer or association between the projects of ai4medicine and the results presented in this work. JBF reported personal fees from Abbvie, AC Immune, Artemida, Bioclinica, Biogen, BMS, Brainomix, Cerevast, Daiichi-Sankyo, Eisai, F.Hoffmann-La Roche AG, Eli Lilly, Guerbet, Ionis Pharmaceuticals, IQVIA, Janssen, Julius clinical, jung diagnostics, Lysogene, Merck, Nicolab, Premier Research, and Tau Rx, outside the submitted work.
